iBio, Inc. Common Stock
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu,… Read more
iBio, Inc. Common Stock (IBIO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.093x
Based on the latest financial reports, iBio, Inc. Common Stock (IBIO) has a cash flow conversion efficiency ratio of -0.093x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.24 Million) by net assets ($56.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
iBio, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how iBio, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
iBio, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of iBio, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CSP Inc
NASDAQ:CSPI
|
-0.065x |
|
United Health Products Inc
PINK:UEEC
|
0.074x |
|
Ilika plc
OTCQX:ILIKF
|
-0.108x |
|
Ege Profil Ticaret ve Sanayi AS
IS:EGPRO
|
0.038x |
|
North European Oil Royalty Trust
NYSE:NRT
|
1.478x |
|
Helius Medical Technologies Inc Class A
NASDAQ:HSDT
|
0.027x |
|
Trajectory Alpha Acquisition Corp
NYSE:TCOA
|
-0.004x |
|
Daedong Gear Co. Ltd
KQ:008830
|
0.047x |
Annual Cash Flow Conversion Efficiency for iBio, Inc. Common Stock (2007–2025)
The table below shows the annual cash flow conversion efficiency of iBio, Inc. Common Stock from 2007 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $14.88 Million | $-15.30 Million | -1.028x | -18.20% |
| 2024-06-30 | $21.32 Million | $-18.55 Million | -0.870x | +56.03% |
| 2023-06-30 | $15.38 Million | $-30.44 Million | -1.979x | -232.32% |
| 2022-06-30 | $63.48 Million | $-37.80 Million | -0.595x | -115.03% |
| 2021-06-30 | $108.57 Million | $-30.06 Million | -0.277x | -17.46% |
| 2020-06-30 | $56.61 Million | $-13.35 Million | -0.236x | +95.86% |
| 2019-06-30 | $2.46 Million | $-13.97 Million | -5.688x | -582.03% |
| 2018-06-30 | $16.16 Million | $-13.48 Million | -0.834x | +43.52% |
| 2017-06-30 | $8.91 Million | $-13.16 Million | -1.477x | -339.80% |
| 2016-06-30 | $24.04 Million | $-8.07 Million | -0.336x | +20.20% |
| 2015-06-30 | $11.23 Million | $-4.72 Million | -0.421x | +37.66% |
| 2014-06-30 | $6.10 Million | $-4.12 Million | -0.675x | +29.47% |
| 2013-06-30 | $5.07 Million | $-4.85 Million | -0.957x | +1.78% |
| 2012-06-30 | $6.17 Million | $-6.01 Million | -0.974x | +96.41% |
| 2011-06-30 | $196.64K | $-5.34 Million | -27.147x | -1144.06% |
| 2010-06-30 | $1.08 Million | $-2.35 Million | -2.182x | -372.91% |
| 2009-06-30 | $4.39 Million | $-2.02 Million | -0.461x | -348.99% |
| 2008-06-30 | $-6.20 Million | $-1.15 Million | 0.185x | -5.46% |
| 2007-06-30 | $-4.33 Million | $-849.38K | 0.196x | -- |